Deficiency of the NF-κB inhibitor caspase activating and recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity

Journal of Immunology

Volumn 179, Issue 7, 2007, Pages 4867-4873

  Fontalba, Ana ^a   Martinez Taboada, Victor ^a   Gutierrez, Olga ^a   Pipaon, Carlos ^a   Benito, Natividad ^a   Balsa, Alejandro ^b   Blanco, Ricardo ^a   Fernandez Luna, Jose L ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN CARD8; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CARD8 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; CELL LINE; DRUG ANTAGONISM; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION;

ARTHRITIS, RHEUMATOID; CARD SIGNALING ADAPTOR PROTEINS; CELL LINE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NF-KAPPA B; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 43049177426     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.7.4867     Document Type: Article

References (38)

1. Yamamoto, Y., and R. B. Gaynor. 2001. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 107: 135-142.
2. Ogura, Y., N. Inohara, A. Benito, F. F. Chen, S. Yamaoka, and G. Nunez. 2001. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J. Biol. Chem. 276: 4812-4818.
3. Ting, J. P., D. L. Kastner, and H. M. Hoffman. 2006. CATERPILLERs, pyrin and hereditary immunological disorders. Nat. Rev. Immunol. 6: 183-195.
4. Manji, G. A., L. Wang, B. J. Geddes, M. Brown, S. Merriam, A. Al-Garawi, S. Mak, J. M. Lora, M. Briskin, M. Jurman, et al. 2002. PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-κB. J. Biol. Chem. 277: 11570-11575.
5. O'Connor, W., Jr., J. A. Harton, X. Zhu, M. W. Linhoff, and J. P. Ting. 2003. Cutting edge: CIAS1/cryopyrin/PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory mediator with NF-κB suppressive properties. J. Immunol. 171: 6329-6333.
6. Bouchier-Hayes, L., H. Conroy, H. Egan, C. Adrain, E. M. Creagh, M. MacFarlane, and S. J. Martin. 2001. CARDINAL, a novel caspase recruitment domain protein, is an inhibitor of multiple NF-κB activation pathways. J. Biol. Chem. 276: 44069-44077.
7. Razmara, M., S. M. Srinivasula, L. Wang, J. L. Poyet, B. J. Geddes, P. S. DiStefano, J. Bertin, and E. S. Alnemri. 2002. CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis. J. Biol. Chem. 277: 13952-13958.
8. Stilo, R., A. Leonardi, L. Formisano, B. Di Jeso, P. Vito, and D. Liguoro. 2002. TUCAN/CARDINAL and DRAL participate in a common pathway for modulation of NF-κB activation. FEBS Lett. 521: 165-169.
9. Inohara, N., T. Koseki, J. Lin, L. del Peso, P. C. Lucas, F. F. Chen, Y. Ogura, and G. Nunez. 2000. An induced proximity model for NF-κB activation in the Nod1/RICK and RIP signaling pathways. J. Biol. Chem. 275: 27823-27831.
10. Fiorentino, L., C. Stehlik, V. Oliveira, M. E. Ariza, A. Godzik, and J. C. Reed. 2002. A novel PAAD-containing protein that modulates NF-κB induction by cytokines tumor necrosis factor-α and interleukin-1β. J. Biol. Chem. 277: 35333-35340.
11. Hoffman, H. M., J. L. Mueller, D. H. Broide, A. A. Wanderer, and R. D. Kolodner. 2001. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29: 301-305.
12. Agostini, L., F. Martinon, K. Burns, M. F. McDermott, P. N. Hawkins, and J. Tschopp. 2004. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20: 319-325.
13. Hugot, J., M. Chamaillard, H. Zouali, S. Lesage, J. Cezard, J. Belaiche, S. Almer, C. Tysk, C. O'Morain, M. Gassull, et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603.
14. Ogura, Y., D. Bonen, N. Inohara, D. Nicolae, F. Chen, R. Ramos, H. Britton, T. Moran, R. Karaliuskas, R. Duerr, et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606.
15. Miceli-Richard, C., S. Lesage, M. Rybojad, A. Prieur, S. Manouvrier-Hanu, R. Hafner, M. Chamaillard, H. Zouali, G. Thomas, and J. Hugot. 2001. CARD15 mutations in Blau syndrome. Nat. Genet. 29: 19-20.
16. Andreakos, E., S. Sacre, B. M. Foxwell, and M. Feldmann. 2005. The Toll-like receptor-nuclear factor κB pathway in rheumatoid arthritis. Front. Biosci. 10: 2478-2488.
17. Marok, R., P. G. Winyard, A. Coumbe, M. L. Kus, K. Gaffney, S. Blades, P. I. Mapp, C. J. Morris, D. R. Blake, C. Kaltschmidt, and P. A. Baeuerle. 1996. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum. 39: 583-591.
18. Arnett, F. C., S. M. Edworthy, D. A. Bloch, D. J. McShane, J. F. Fries, N. S. Cooper, L. A. Healey, S. R. Kaplan, M. H. Liang, H. S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324.
19. Gutierrez, O., C. Pipaon, N. Inohara, A. Fontalba, Y. Ogura, F. Prosper, G. Nunez, and J. L. Fernandez-Luna. 2002. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB activation. J. Biol. Chem. 277: 41701-41705.
20. Inohara, N., Y. Ogura, A. Fontalba, O. Gutierrez, F. Pons, J. Crespo, K. Fukase, S. Inamura, S. Kusumoto, M. Hashimoto, et al. 2003. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J. Biol. Chem. 278: 5509-5512.
21. Inohara, N., Y. Ogura, F. F. Chen, A. Muto, and G. Nunez. 2001. Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J. Biol. Chem. 276: 2551-2554.
22. Benito, A., M. Silva, D. Grillot, G. Nunez, and J. Fernandez-Luna. 1996. Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-xL. Blood 87: 3837-3843.
23. May, M., and S. Ghosh. 1998. Signal transduction through NF-κB. Immunol. Today 19: 80-88.
24. Pinals, R. S., A. T. Masi, and R. A. Larsen. 1981. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 24: 1308-1315.
25. Gonzalez-Alvaro, I., L. Carmona, A. Balsa, R. Sanmarti, M. A. Belmonte, and X. Tena. 2003. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J. Rheumatol. 30: 697-704.
26. Welsing, P. M., A. M. van Gestel, H. L. Swinkels, L. A. Kiemeney, and P. L. van Riel. 2001. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 44: 2009-2017.
27. Fransen, J., and P. L. van Riel. 2005. The Disease Activity Score and the EULAR response criteria. Clin. Exp. Rheumatol. 23: S93-S99.
28. Ghosh, S., M. J. May, and E. B. Kopp. 1998. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16: 225-260.
29. Courtois, G., and T. D. Gilmore. 2006. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene 25: 6831-6843.
30. Courtois, G., A. Smahi, J. Reichenbach, R. Doffinger, C. Cancrini, M. Bonnet, A. Puel, C. Chable-Bessia, S. Yamaoka, J. Feinberg, et al. 2003. A hypermorphic IκBα mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J. Clin. Invest. 112: 1108-1115.
31. Janssen, R., A. van Wengen, M. A. Hoeve, M. ten Dam, M. van der Burg, J. van Dongen, E. van de Vosse, M. van Tol, R. Bredius, T. H. Ottenhoff, et al. 2004. The same IκBα mutation in two related individuals leads to completely different clinical syndromes. J. Exp. Med. 200: 559-568.
32. Smahi, A., G. Courtois, P. Vabres, S. Yamaoka, S. Heuertz, A. Munnich, A. Israel, N. S. Heiss, S. M. Klauck, P. Kioschis, et al. 2000. Genomic rearrangement in NEMO impairs NF-κB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 405: 466-472.
33. Makarov, S. S. 2001. NF-κB in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res. 3: 200-206.
34. Marok, R., P. G. Winyard, A. Coumbe, M. L. Kus, K. Gaffney, S. Blades, P. I. Mapp, C. J. Morris, D. R. Blake, C. Kaltschmidt, and P. A. Baeuerle. 1996. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum. 39: 583-591.
35. van der Heijde, D. M., P. L. van Riel, M. A. van Leeuwen, M. A. van 't Hof, M. H. van Rijswijk, and L. B. van de Putte. 1992. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br. J. Rheumatol. 31: 519-525.
36. McGovern, D. P., H. Butler, T. Ahmad, M. Paolucci, D. A. van Heel, K. Negoro, P. Hysi, J. Ragoussis, S. P. Travis, L. R. Cardon, and D. P. Jewell. 2006. TUCAN (CARD8) genetic variants and inflammatory bowel disease. Gastroenterology 131: 1190-1196.
37. Seetharaman, R., A. L. Mora, G. Nabozny, M. Boothby, and J. Chen. 1999. Essential role of T cell NF-κB activation in collagen-induced arthritis. J. Immunol. 163: 1577-1583.
38. Miagkov, A. V., D. V. Kovalenko, C. E. Brown, J. R. Didsbury, J. P. Cogswell, S. A. Stimpson, A. S. Baldwin, and S. S. Makarov. 1998. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl. Acad. Sci. USA 95: 13859-13864.